Harmony Biosciences Holdings (HRMY) Non-Current Debt (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted Non-Current Debt of $138.8 million for Q1 2026, down 3.38% sequentially from $143.7 million in Q4 2025, and down 12.24% YoY from $158.2 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Non-Current Debt (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Non-Current Debt for 8 years, with the latest figure at $138.8 million in Q1 2026.
- Quarterly Non-Current Debt fell 12.24% year-over-year to $138.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138.8 million (down 12.24% YoY) and the FY2025 annual result came in at $143.7 million, down 11.87% from the prior year.
- Non-Current Debt retreated to $138.8 million in Q1 2026 per HRMY's latest filing, from $143.7 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $189.9 million in Q1 2022 and troughed at $138.8 million in Q1 2026.
- A 5-year average of $170.9 million and a median of $175.0 million in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2026: Non-Current Debt slipped 0.18% in 2022, then retreated 12.24% in 2026.
- Over 5 years, Non-Current Debt stood at $189.6 million in 2022, then dropped by 5.84% to $178.6 million in 2023, then declined by 8.71% to $163.0 million in 2024, then dropped by 11.87% to $143.7 million in 2025, then declined by 3.38% to $138.8 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $138.8 million, $143.7 million, and $148.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 133.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 133.96 Mn |
| Mar 31, 2026 | 138.81 Mn |
| Dec 31, 2025 | 143.66 Mn |
| Sep 30, 2025 | 148.51 Mn |
| Jun 30, 2025 | 153.35 Mn |
| Mar 31, 2025 | 158.18 Mn |
| Dec 31, 2024 | 163.02 Mn |
| Sep 30, 2024 | 167.85 Mn |
| Jun 30, 2024 | 171.42 Mn |
| Mar 31, 2024 | 175.00 Mn |
| Dec 31, 2023 | 178.57 Mn |
| Sep 30, 2023 | 182.13 Mn |
| Jun 30, 2023 | 180.49 Mn |
| Mar 31, 2023 | 185.06 Mn |
| Dec 31, 2022 | 189.65 Mn |
| Sep 30, 2022 | 189.73 Mn |
| Jun 30, 2022 | 189.81 Mn |
| Mar 31, 2022 | 189.90 Mn |
| Dec 31, 2021 | 189.98 Mn |
| Sep 30, 2021 | 190.07 Mn |